Today in a letter to the Department of Justice (DOJ) the AHA raised concerns about the proposed Anthem acquisition of Cigna focusing on the impact of Anthem’s affiliation with the Blue Cross Blue Shield System.

The letter states:

“Previous investigations also suggest that increased Blue plan market power will raise, not lower, premiums to consumers. We would expect that same impact on premiums in any state with a dominant or near-dominant Blue plan that gains any additional market power as a result of this acquisition.  And, no speculative claim of efficiency gains by the parties can offset the likelihood that premiums will increase for consumers as a result of this transaction.

Finally, the temptation for dominant plans to abuse their market power will only increase as a result of this acquisition.  Some dominant Blue plans already have the financial and other means to undermine or defeat entry or expansion by other plans, even established plans.  Eliminating a national competitor better able to withstand the onslaught of a variety of anticompetitive tactics will almost certainly embolden this conduct, thereby harming, perhaps irreparably, any chance of increasing competition and consumer choice.”

The AHA continues to ask DOJ to challenge this acquisition and examine the impact on competition, including the increase in barriers to competition in states where Anthem is not the Blue plan because we believe this deal threatens to undermine reform by discouraging or blocking entirely new entry and entrenching already dominant insurers across the nation.

Related News Articles

Headline
In this conversation, Dylan Panuska, clinical psychologist and manager of behavioral health integration with Endeavor Health, showcases examples of how…
Headline
The Office for Civil Rights in the Department of Health and Human Services Dec. 5 issued a letter to health care providers and others clarifying language…
Headline
The Congressional Budget Office Dec. 5 informed Congress that 2.2 million consumers would lose their health insurance in 2026 if enhanced premium subsidies are…
Perspective
December’s holiday rush is in full swing on Capitol Hill as Congress returned to Washington this week facing a long list of to-dos and a short time to do them…
Headline
The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of Lyfgenia) and Vertex…
Headline
The Department of Health and Human Services' Government Accountability Office Nov. 14 released a report that determined the private health insurance market…